Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women—Data From a Multicenter French Registry

Author:

Providência Rui12,Marijon Eloi3,Lambiase Pier D.2,Bouzeman Abdeslam1,Defaye Pascal4,Klug Didier5,Amet Denis3,Perier Marie‐Cécile6,Gras Daniel7,Algalarrondo Vincent8,Deharo Jean‐Claude9,Leclercq Christophe10,Fauchier Laurent11,Babuty Dominique11,Bordachar Pierre12,Sadoul Nicolas13,Piot Olivier14,Boveda Serge1,Providencia Rui,Beganton Frankie,Perier Marie‐Cecile,

Affiliation:

1. Clinique Pasteur, Toulouse, France

2. Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom

3. European Georges Pompidou Hospital and Paris Descartes University, Paris, France

4. CHU Michallon, Grenoble, France

5. CHRU Lille, Lille, France

6. Paris Cardiovascular Research Center, Inserm U970, Paris, France

7. Nouvelles Cliniques Nantaises, Nantes, France

8. CHU Antoine Béclère, Clamart, France

9. CHU La Timone, Marseille, France

10. CHU Pontchaillou, Rennes, France

11. CHU Trousseau, Tours, France

12. CHU Haut Lévêque, Bordeaux, France

13. CHU Brabois, Nancy, France

14. Centre Cardiologique du Nord, Saint Denis, France

Abstract

Background There are limited data describing sex specificities regarding implantable cardioverter defibrillators (ICDs) in the real‐world European setting. Methods and Results Using a large multicenter cohort of consecutive patients referred for ICD implantation for primary prevention (2002–2012), in ischemic and nonischemic cardiomyopathy, we examined the sex differences in subjects' characteristics and outcomes. Of 5539 patients, only 837 (15.1%) were women and 53.8% received cardiac resynchronization therapy. Compared to men, women presented a significantly higher proportion of nonischemic cardiomyopathy (60.2% versus 36.2%, P <0.001), wider QRS complex width (QRS >120 ms: 74.6% versus 68.5%, P =0.003), higher New York Heart Association functional class (≥III in 54.2%♀ versus 47.8%♂, P =0.014), and lower prevalence of atrial fibrillation (18.7% versus 24.9%, P <0.001). During a 16 786 patient‐years follow‐up, overall, fewer appropriate therapies were observed in women (hazard ratio=0.59, 95% CI 0.45–0.76; P <0.001). By contrast, no sex‐specific interaction was observed for inappropriate shocks (odds ratio ♀=0.84, 95% CI 0.50–1.39, P =0.492), early complications (odds ratio=1.00, 95% CI 0.75–1.32, P =0.992), and all‐cause mortality (hazard ratio=0.87 95% CI 0.66–1.15, P =0.324). Analysis of sex‐by‐ cardiac resynchronization therapy interaction shows than female cardiac resynchronization therapy recipients experienced fewer appropriate therapies than men (hazard ratio=0.62, 95% CI 0.50–0.77; P <0.001) and lower mortality (hazard ratio=0.68, 95% CI 0.47–0.97; P =0.034). Conclusions In our real‐life registry, women account for the minority of ICD recipients and presented with a different clinical profile. Whereas female cardiac resynchronization therapy recipients had a lower incidence of appropriate ICD therapies and all‐cause death than their male counterparts, the observed rates of inappropriate shocks and early complications in all ICD recipients were comparable. Clinical Trial Registration URL: https://www.clinicaltrials.gov/ . Unique identifier: NCT01992458.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 56 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3